Detalles de la búsqueda
1.
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Br J Cancer
; 130(8): 1269-1278, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402342
2.
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.
Ann Oncol
; 32(1): 66-76, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098997
3.
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Ann Oncol
; 31(1): 88-95, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31912801
4.
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
Ann Oncol
; 29(9): 1955-1963, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30010751
5.
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
Ann Oncol
; 29(5): 1099-1107, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438451
6.
The role of the general practitioner and the out-of-hospital public rheumatologist in the diagnosis and follow-up of patients with polymyalgia rheumatica.
Reumatismo
; 70(1): 44-50, 2018 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29589402
7.
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Br J Cancer
; 117(9): 1269-1277, 2017 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29065426
8.
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.
Ann Oncol
; 28(5): 922-930, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28453700
9.
Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study.
Int J Cancer
; 139(1): 205-11, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26915905
10.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Ann Oncol
; 27(11): 2074-2081, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27573560
11.
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Ann Oncol
; 27(8): 1386-422, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27380959
12.
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol
; 26(8): 1547-73, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26026162
13.
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Ann Oncol
; 26(10): 2085-91, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272806
14.
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Ann Oncol
; 25(1): 107-16, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356622
15.
Reply to the letter to the editor: 'The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?' By P. Trendsz et al.
Ann Oncol
; 29(8): 1883-1884, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29912278
16.
Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.
Ann Oncol
; 28(9): 2043-2044, 2017 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28911090
17.
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol
; 28(11): 2901-2905, 2017 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27604385
18.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Ann Oncol
; 28(12): 3110, 2017 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327986
19.
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
Ann Oncol
; 23(10): 2479-2516, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23012255
20.
A tribute to biologics in advanced colorectal cancer treatment.
Ann Oncol
; 27(8): 1372-4, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27358377